Tumour ischaemia by interferon-γ resembles physiological blood vessel regression

Nature

Volumn 545, Issue 7652, 2017, Pages 98-102

  Kammertoens, Thomas ^a,b   Friese, Christian ^a,b   Arina, Ainhoa ^c   Idel, Christian ^c,j   Briesemeister, Dana ^a,b   Rothe, Michael ^a,b   Ivanov, Andranik ^a,d   Szymborska, Anna ^b   Patone, Giannino ^b   Kunz, Severine ^b   Sommermeyer, Daniel ^b   Engels, Boris ^b   Leisegang, Matthias ^a,b,d   Textor, Ana ^a,b   Joerg Fehling, Hans ^e   Fruttiger, Marcus ^f   Lohoff, Michael ^g   Herrmann, Andreas ^h   Yu, Hua ^h   Weichselbaum, Ralph ^c   Uckert, Wolfgang ^b,d   Hübner, Norbert ^a,b,i   Gerhardt, Holger ^b,d,i   Beule, Dieter ^b,d   Schreiber, Hans ^a,c,d   Blankenstein, Thomas ^a,b,d   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d BERLIN INSTITUTE OF HEALTH   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^j UNIVERSITY OF LÜBECK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; TUMOR NECROSIS FACTOR; INTERFERON RECEPTOR;

BLOOD; CANCER; CELLS AND CELL COMPONENTS; GROWTH RATE; PHYSIOLOGY; PREGNANCY; PROTEIN; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FIBROBLAST; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INTRAVITAL MICROSCOPY; ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ISCHEMIA; TUMOR NECROSIS; TUMOR REGRESSION; TUMOR VASCULARIZATION; WOUND HEALING; ANIMAL; BIOSYNTHESIS; BLOOD VESSEL; CELL HYPOXIA; ENDOTHELIUM CELL; ENZYME SPECIFICITY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; NECROSIS; NEOPLASM; PATHOLOGY; STROMA CELL; TUMOR CELL LINE; VASCULAR REMODELING; VASCULARIZATION;

MUS;

ANIMALS; BLOOD VESSELS; CELL HYPOXIA; CELL LINE, TUMOR; ENDOTHELIAL CELLS; FEMALE; INTERFERON-GAMMA; INTRAVITAL MICROSCOPY; ISCHEMIA; MALE; MICE; NECROSIS; NEOPLASMS; RECEPTORS, INTERFERON; STROMAL CELLS; SUBSTRATE SPECIFICITY; VASCULAR REMODELING; WOUND HEALING;

EID: 85018417861     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22311     Document Type: Article

References (41)

1. Blankenstein, T. The role of tumor stroma in the interaction between tumor and immune system. Curr. Opin. Immunol. 17, 180-186 (2005).
2. Dighe, A. S., Richards, E., Old, L. J., Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN receptors. Immunity 1, 447-456 (1994).
3. Braumüller, H., et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361-365 (2013).
4. Zhang, B., Karrison, T., Rowley, D. A., Schreiber, H. IFN-A nd TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118, 1398-1404 (2008).
5. Listopad, J. J., et al. Fas expression by tumor stroma is required for cancer eradication. Proc. Natl Acad. Sci. USA 110, 2276-2281 (2013).
6. Franco, C. A., et al. Dynamic endothelial cell rearrangements drive developmental vessel regression. PLoS Biol. 13, e1002125 (2015).
7. Bodnar, R. J., Yates, C. C., Rodgers, M. E., Du, X., Wells, A. IP-10 induces dissociation of newly formed blood vessels. J. Cell Sci. 122, 2064-2077 (2009).
8. Ashkar, A. A., Di Santo, J. P., Croy, B. A. Interferon contributes to initiation of uterine vascular modification, decidual integrity, uterine natural killer cell maturation during normal murine pregnancy. J. Exp. Med. 192, 259-270 (2000).
9. Schreiber, K., Rowley, D. A., Riethmüller, G., Schreiber, H. Cancer immunotherapy and preclinical studies: Why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 20, 567-584 (2006).
10. Corthay, A., et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22, 371-383 (2005).
11. Lu, Y., et al. Responsiveness of stromal fibroblasts to IFN-blocks tumor growth via angiostasis. J. Immunol. 183, 6413-6421 (2009).
12. Qin, Z., Blankenstein, T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN receptor expression by nonhematopoietic cells. Immunity 12, 677-686 (2000).
13. Qin, Z., et al. A critical requirement of interferon-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63, 4095-4100 (2003).
14. Coughlin, C. M., et al. Tumor cell responses to IFN affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9, 25-34 (1998).
15. Luster, A. D., Unkeless, J. C., Ravetch, J. V.-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672-676 (1985).
16. Sgadari, C., et al. Mig, the monokine induced by interferon-, promotes tumor necrosis in vivo. Blood 89, 2635-2643 (1997).
17. Deng, J., et al. IFN-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. J. Pathol. 233, 170-182 (2014).
18. Tellides, G., et al. Interferon-elicits arteriosclerosis in the absence of leukocytes. Nature 403, 207-211 (2000).
19. Briesemeister, D., et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int. J. Cancer 128, 371-378 (2011).
20. Anders, K., et al. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell 20, 755-767 (2011).
21. Mazzieri, R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512-526 (2011).
22. Schietinger, A., et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. OncoImmunology 2, e26677 (2013).
23. Hock, H., et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon . Proc. Natl Acad. Sci. USA 90, 2774-2778 (1993).
24. Augustin, H. G., Braun, K., Telemenakis, I., Modlich, U., Kuhn, W. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am. J. Pathol. 147, 339-351 (1995).
25. Modlich, U., Kaup, F. J., Augustin, H. G. Cyclic angiogenesis and blood vessel regression in the ovary: Blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab. Invest. 74, 771-780 (1996).
26. Guo, S., et al. IRF4 is a novel mediator for neuronal survival in ischaemic stroke. Cell Death Differ. 21, 888-903 (2014).
27. Rothstein, J. L., Schreiber, H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc. Natl Acad. Sci. USA 85, 607-611 (1988).
28. Johansson, A., Hamzah, J., Payne, C. J., Ganss, R. Tumor-targeted TNF stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl Acad. Sci. USA 109, 7841-7846 (2012).
29. Refaeli, Y., Van Parijs, L., Alexander, S. I., Abbas, A. K. Interferon is required for activation-induced death of T lymphocytes. J. Exp. Med. 196, 999-1005 (2002).
30. Hemmi, S., et al. Cloning of murine interferon gamma receptor cDNA: Expression in human cells mediates high-affinity binding but is not sufficient to confer sensitivity to murine interferon gamma. Proc. Natl Acad. Sci. USA 86, 9901-9905 (1989).
31. Sakai, K., Mitani, K., Miyazaki, J. Efficient regulation of gene expression by adenovirus vector-mediated delivery of the CRE recombinase. Biochem. Biophys. Res. Commun. 217, 393-401 (1995).
32. Staveley-O'Carroll, K., et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171, 697-707 (2003).
33. Bhowmick, N. A., et al. TGF-signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
34. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R., Förster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).
35. Claxton, S., et al. Efficient, inducible Cre-recombinase activation in vascular endothelium. Genesis 46, 74-80 (2008).
36. Luche, H., Weber, O., Nageswara Rao, T., Blum, C., Fehling, H. J. Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43-53 (2007).
37. Mittrücker, H. W., et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540-543 (1997).
38. Willimsky, G., Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005).
39. Textor, A., et al. Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J. Exp. Med. 213, 2333-2348 (2016).
40. Li, L. P., Schlag, P. M., Blankenstein, T. Transient expression of SV 40 large T antigen by Cre/LoxP-mediated site-specific deletion in primary human tumor cells. Hum. Gene Ther. 8, 1695-1700 (1997).
41. Schindelin, J., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676-682 (2012).